INDP Indaptus Therapeutics, Inc.
Financings ·
Indaptus sold 20,338,974 shares for approximately $24.0 million after the closing date was pushed back. Its cash was $7.6 million at June 30, 2026, and its 2025 net loss was $20.8 million.
Five buyers including Yun Yao and Sino Lion Ventures Limited bought preferred stock that could convert into 108,936,000 shares. The board appointed Junyi Dai chairman and chief executive officer, and four directors resigned on March 18, 2026.
Stockholders approved conversion of preferred stock that, once converted, would give David Lazar 111.0 million common shares, about 96.4% of the fully diluted common stock. They also approved up to two reverse stock splits and authorized shares rising to 1,000,000,000.
The stock closed at $1.00 or higher for 10 consecutive business days from June 27, 2025 to July 11, 2025. Nasdaq considers the matter closed.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $9.3 million | $7.3 million |
| Net income (loss) | -$20.8 million | -$15.0 million |
| Cash from operations | -$14.8 million | -$12.3 million |
| Cash and equivalents | $8.5 million | $5.8 million |
Our latest story on this, dated Feb 27, 2026: "Indaptus stockholders approve preferred stock conversion and reverse split range". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 20, 2026: "Indaptus Therapeutics closes $24.0 million private placement of 20,338,974 shares". The story links the filing or release it is based on. Read the story.
Indaptus Therapeutics, Inc. trades under the ticker INDP on NASDAQ.
Indaptus Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Indaptus Therapeutics, Inc. is 1857044. Its filings are on SEC EDGAR.
133,242,324 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Indaptus Therapeutics, Inc. under United States.
Our directory classifies Indaptus Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Indaptus Therapeutics, Inc. is US45339J2042.
aibio.space lists Indaptus Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Indaptus Therapeutics, Inc. reported a net loss of $20.8 million for the fiscal year ended Dec 31, 2025, and used $14.8 million of cash in operations, per its annual report to the SEC.
$9.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
$11.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Indaptus Therapeutics, dated Oct 20, 2026: "Indaptus Therapeutics closes $24.0 million private placement of 20,338,974 shares". Indaptus sold 20,338,974 shares for approximately $24.0 million after the closing date was pushed back. Its cash was $7.6 million at June 30, 2026, and its 2025 net loss was $20.8 million. Source.
Reported a financing. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.01,5.03,5.07,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,3.03,5.02,5.03,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio